GnRH Antagonist Prevention of Premature Luteinization in Patients Undergoing IUI
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 662
- 试验地点
- 1
- 主要终点
- Pregnancy rate
研究概览
简要总结
Premature luteinization in patients undergoing IUI can occur in up to 24% of cycles. These patients, according to recent data, have a lower pregnancy rate than controls. The possibility to avoid premature luteinization with GnRH antagonist may restore the chances of achieving a pregnancy in these women.
详细描述
The purpose of this study was to investigate whether a subset of patients benefits from GnRHa administration during IUI. PL was tested for in patients who were undergoing artificial insemination procedures, and the effect of GnRHa on PR in patients who
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •previous failed IUI cycle with premature luteinization
排除标准
- •39 years or older
- •not eligible for IUI (patent tubes, > 3 million capacitated spermatozoa)
- •4 previous IUI cycles
研究组 & 干预措施
Ganirelix
Patients with premature lutenization (progesterone >1,2 ng/ml) who did not get pregnant during the first IUI underwent a second IUI.
干预措施: Ganirelix (Drug)
结局指标
主要结局
Pregnancy rate
时间窗: 2 weeks after intervention
次要结局
- premature luteinization(at the time of intervention)
研究者
Juan A Garcia-Velasco
MD
IVI Madrid